Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam.

The research focuses on studying how intravenous alfaxalone, a drug used for anesthesia, behaves in the body and how it affects young Thoroughbred horses. The horses were administered with two different doses of this drug after being pre-treated with medetomidine and midazolam. The researchers analyzed the collected blood samples to measure several factors like the time taken for the drug to be half eliminated from the body, volume of distribution, and total clearance rate.

Methods Used in the Study

• Seven Thoroughbred horses were randomly selected to participate in the study. Each horse was anaesthetized twice, once with a 1mg/kg dose of intravenous alfaxalone, and once with a 2mg/kg dose.
• Prior to anesthesia, horses were premedicated with medetomidine and midazolam, drugs commonly used in veterinary medicine as sedatives and muscle relaxants respectively.
• Blood samples were obtained at specific intervals for two hours after the administration of alfaxalone and analyzed using a method called liquid chromatography tandem-mass spectrometry. This process helps to accurately measure the concentration of alfaxalone in the plasma, an important aspect of pharmacokinetics.

Findings of the Study

• Both the 1mg/kg and 2mg/kg doses resulted in good to excellent induction and recovery in the horses. However, recovery time was significantly longer for the 2mg/kg dose (about 90 minutes) as compared to the 1mg/kg dose (about 50 minutes).
• The higher dose also resulted in a significantly lower respiratory rate leading to hypoxemia, a deficient level of oxygen in the blood.
• The researchers also measured the elimination half-life, total clearance, and volume of distribution for each dose. For the 1mg/kg dose, these parameters were approximately 58.2 minutes, 11.6 ml/minute/kg, and 0.8 l/kg respectively. For the 2mg/kg dose, they were about 59.8 minutes, 14.7 ml/minute/kg, and 0.9 l/kg respectively.
• These measurements indicate that alfaxalone is rapidly eliminated from the plasma in young Thoroughbred horses.

Implications of the Research

• The results of the study provide valuable insights into the pharmacokinetics and pharmacodynamics of alfaxalone in young Thoroughbred horses. Understanding how this drug moves through and affects the horse’s body can help in optimizing dosage and minimizing potential side effects when used in clinical settings.
• Given that a higher dose of alfaxalone led to respiratory depression and prolonged recovery time, the study suggests that caution is needed when administering higher doses of the drug, particularly in cases where respiratory complications might be of concern.